Equities analysts forecast that Histogenics Corp (NASDAQ:HSGX) will announce earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Histogenics’ earnings, with estimates ranging from ($0.33) to ($0.28). Histogenics reported earnings of ($1.60) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 80.6%. The firm is expected to report its next quarterly earnings report before the market opens on Thursday, March 15th.
On average, analysts expect that Histogenics will report full-year earnings of ($1.02) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.02) to ($0.62). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Histogenics.
HSGX has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Histogenics from a “buy” rating to a “hold” rating in a report on Thursday, December 28th. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price target on shares of Histogenics in a report on Tuesday, November 21st. Canaccord Genuity reaffirmed a “buy” rating and issued a $4.00 price target on shares of Histogenics in a report on Thursday, December 21st. Finally, ValuEngine raised shares of Histogenics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Histogenics (HSGX) traded up $0.24 during trading hours on Friday, reaching $3.04. 347,457 shares of the company were exchanged, compared to its average volume of 147,627. Histogenics has a 12 month low of $1.55 and a 12 month high of $3.13. The stock has a market capitalization of $69.90, a PE ratio of -2.03 and a beta of 1.83.
Several hedge funds and other institutional investors have recently bought and sold shares of HSGX. Virtu Financial LLC raised its holdings in shares of Histogenics by 413.4% in the fourth quarter. Virtu Financial LLC now owns 63,563 shares of the biotechnology company’s stock worth $130,000 after buying an additional 51,182 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Histogenics by 71.1% in the fourth quarter. Deutsche Bank AG now owns 71,706 shares of the biotechnology company’s stock worth $146,000 after buying an additional 29,806 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Histogenics by 54.8% in the fourth quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock worth $497,000 after buying an additional 85,800 shares during the last quarter. Finally, Sabby Management LLC raised its holdings in shares of Histogenics by 98.3% in the fourth quarter. Sabby Management LLC now owns 955,060 shares of the biotechnology company’s stock worth $1,958,000 after buying an additional 473,393 shares during the last quarter. 50.45% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/03/14/zacks-brokerages-expect-histogenics-corp-nasdaqhsgx-will-post-earnings-of-0-31-per-share.html.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.